SCHEMBL3774546

SCHEMBL3774546

O=C(CN1CCN(C(=O)C(c2ccccc2)c2ccccc2)CC1)N1CCN(C2CCC2)CC1

nearest known ligand 0.54

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
CHRM1 P11229 3/20 0.54
KDM4E B2RXH2 6/20 0.53
ALDH1A1 P00352 6/20 0.53
TSHR P16473 3/20 0.49
NPSR1 Q6W5P4 2/20 0.49
LMNA P02545 1/20 0.49
PARP1 P09874 1/20 0.48
PKM P14618 1/20 0.48
MAPT P10636 2/20 0.48
GAA P10253 1/20 0.47
MEN1 O00255 1/20 0.46
HTT P42858 1/20 0.46
KMT2A Q03164 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3765502 0.94 CHRM1 (0.48) CHRM1KDM4EALDH1A1TSHRNPSR1
SCHEMBL3770051 0.87 CHRM1 (0.56) CHRM1KDM4EALDH1A1TSHRNPSR1
SCHEMBL3773262 0.87 CHRM3 (0.60) CHRM1KDM4EALDH1A1TSHRNPSR1
SCHEMBL13005947 0.86 CHRM3 (0.61) CHRM1KDM4EALDH1A1TSHRNPSR1
SCHEMBL3763250 0.86 MEN1 (0.57) CHRM1KDM4EALDH1A1TSHRNPSR1
SCHEMBL13004966 0.83 NPSR1 (0.67) KDM4EALDH1A1NPSR1LMNAPKM
SCHEMBL3767674 0.81 ALDH1A1 (0.74) KDM4EALDH1A1TSHRNPSR1LMNA
SCHEMBL3770368 0.81 KDM4E (0.67) KDM4EALDH1A1PARP1MEN1HTT
SCHEMBL3770129 0.81 ALDH1A1 (0.80) KDM4EALDH1A1TSHRLMNAPARP1
SCHEMBL3767216 0.81 KDM4E (0.52) CHRM1KDM4EALDH1A1TSHRNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
WO-2007016496-A2 DIPIPERAZINYL KETONES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2007-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049571-A1 Dipiperazinyl ketones and related analogues HRH4, HRH3, HRH1 CHRM1 392/4885KDM4E 534/4885ALDH1A1 1210/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.